EverPoint Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-450,000
Closed -$29.5M 528
2015
Q4
$29.5M Buy
450,000
+60,000
+15% +$3.71M 0.62% 30
2015
Q3
$22M Buy
390,000
+240,000
+160% +$15.6M 0.57% 41
2015
Q2
$8.87M Sell
150,000
-350,000
-70% -$21.6M 0.16% 192
2015
Q1
$31.1M Buy
500,000
+10,000
+2% +$581K 0.59% 35
2014
Q4
$28.2M Sell
490,000
-85,000
-15% -$4.74M 0.63% 31
2014
Q3
$30.9M Sell
575,000
-475,000
-45% -$25.2M 0.71% 24
2014
Q2
$55M Buy
+1,050,000
New +$53.7M 1.14% 7

Other funds holding TEVA

EverPoint Asset Management's TEVA Position: Q1 2016 in Review

EverPoint Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 450,000 shares — an estimated $29.5M sold.

EverPoint Asset Management first reported a position in TEVA in Q2 2014 and held it in 7 quarters. The position peaked at $55M in Q2 2014. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

  • EverPoint Asset Management reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • EverPoint Asset Management sold 450,000 Teva Pharmaceuticals shares in Q1 2016, an estimated $29.5M.
  • EverPoint Asset Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 7 quarters.
  • EverPoint Asset Management's Teva Pharmaceuticals position peaked at $55M in Q2 2014.
  • 836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on EverPoint Asset Management's 13F filing for Q1 2016, filed 16 May 2016.